Amgen Inc’s experimental obesity drug demonstrated promising durability trends in an early trial. Photo: Reuters/File
Amgen Inc’s experimental obesity drug demonstrated promising durability trends in an early trial. Photo: Reuters/File

Amgen’s experimental obesity drug shows promise in trials, with only mild side effects

  • The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug
  • 150 days after the last dose, patients maintained weight loss had dropped to 11.2 per cent below original weight at the start of the trial

Amgen Inc’s experimental obesity drug demonstrated promising durability trends in an early trial. Photo: Reuters/File
Amgen Inc’s experimental obesity drug demonstrated promising durability trends in an early trial. Photo: Reuters/File
READ FULL ARTICLE